GPhA: 'Up-scheduling' hydrocodone combos will impede patient access, won't curb abuse
This article was originally published in Scrip
Ahead of a two-day meeting of the FDA's Drug Safety and Risk Management Advisory Committee (DSaRM), in which regulators are seeking advice about whether to "up-schedule" hydrocodone combination medicines, such as Vicodin (acetaminophen-hydrocodone), from Schedule III controlled substance status to the more stringent Schedule II, the Generic Pharmaceutical Association (GPhA) argued that taking such action could prevent patients with acute, sub-acute or chronic pain from accessing the drugs.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.